AN2 Therapeutics Inc (ANTX)
2.56
+0.02
(+0.79%)
USD |
NASDAQ |
May 03, 16:00
2.55
-0.01
(-0.39%)
After-Hours: 20:00
AN2 Therapeutics Cash from Investing (TTM): -43.28M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -43.28M |
| September 30, 2023 | -37.64M |
| June 30, 2023 | 22.50M |
| March 31, 2023 | -24.86M |
| December 31, 2022 | -21.77M |
| Date | Value |
|---|---|
| September 30, 2022 | -21.58M |
| June 30, 2022 | -26.25M |
| March 31, 2022 | -36.05M |
| December 31, 2021 | -50.02M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-50.02M
Minimum
Dec 2021
22.50M
Maximum
Jun 2023
-26.55M
Average
-26.25M
Median
Jun 2022
Cash from Investing (TTM) Benchmarks
| Gilead Sciences Inc | -3.646B |
| QuidelOrtho Corp | -187.60M |
| CymaBay Therapeutics Inc (DELISTED) | -86.57M |
| Insmed Inc | -223.60M |
| Revance Therapeutics Inc | 109.74M |